Professor Alan Palmer

Alan Palmer brings extensive board-level experience to his roles in various organisations. Currently serving as a Trustee at The Brain Tumour Charity, the British Neuroscience Association, and One Nucleus - a prominent membership organisation in the life science and healthcare industry, Alan is dedicated to advancing crucial causes.

Furthermore, Alan holds the position of Visiting Professor at Reading University. Beyond his commitment to academia, he is the CEO and co-founder of Elixa MediScience, a pioneering company with a primary focus on discovering ground-breaking medicines to decelerate the progression of neurodegenerative diseases.

Alan's impact extends to the scientific community, having authored over 100 influential papers. His contributions have been particularly significant in the realms of Alzheimer's disease and traumatic brain injury.

As a co-founder of the first UK neuroscience-based start-up, Cerebrus Ltd (now Vernalis PLC), alongside Professor Sir Chris Evans, and the establishment of Pharmidex, a thriving contract research organisation in the medicines research field, Alan has played a pivotal role in shaping successful ventures.Recognized for his entrepreneurial prowess, Alan was honoured as the London Biotechnology Network Entrepreneur of the Year in 2005.

Academically, Alan holds a BSc degree in Biochemistry from Warwick University, as well as an MSc and a PhD from the University of London. He is also a former Faculty member at the University of Pittsburgh. His distinguished standing is further underscored by being a Fellow of both the Royal Society of Biology and the Learned Society of Wales, in addition to being an Honorary member of the Society for Medicines Research. Alan's multifaceted expertise and unwavering dedication make him a prominent figure in the intersection of science, business, and charities.

Next
Next

Shelia Kissane-Marshall